3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
8
Head & Neck
2
Dermatologic
2
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
63
Colorectal Neoplasms
30
Biliary Tract Neoplasms
29
Cholangiocarcinoma
27
Pancreatic Neoplasms
26
Liver Neoplasms
18
Stomach Neoplasms
13
Esophageal Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
10
Gallbladder Neoplasms
9
Adenocarcinoma Of Esophagus
9
Neoplasm Metastasis
8
Esophageal Squamous Cell Carcinoma
8
Ovarian Neoplasms
7
Melanoma
7
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
6
Carcinoma, Renal Cell
6
Carcinoma
6
Bile Duct Neoplasms
6
Triple Negative Breast Neoplasms
5
Rectal Neoplasms
5
Prostatic Neoplasms
5
Colonic Neoplasms
5
Uterine Cervical Neoplasms
4
Lung Neoplasms
4
Diabetes Mellitus, Insulin-Dependent, 12
4
Adenocarcinoma
4
Neoplasms
3
Interventions
pembrolizumab
13
Gemcitabine
12
Cyclophosphamide
10
Carboplatin
10
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Cisplatin
8
Docetaxel
7
X-Rays
6
Filgrastim
6
Doxorubicin
6
Biopsy
6
tislelizumab
5
Radiosurgery
5
Phantoms, Imaging
5
Paclitaxel
5
Nivolumab
5
Irinotecan
5
Bevacizumab
5
130-nm albumin-bound paclitaxel
5
spartalizumab
4
palbociclib
4
Thiotepa
4
Temozolomide
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Mesna
4
Ipilimumab
4
Imatinib Mesylate
4
Ifosfamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
durvalumab
×
Gastrointestinal
×
Clear all
NCT04705818
2026-03-06
CAIRE
Institut Bergonié
Phase 2
Completed
164 enrolled